Akebia Therapeutics (AKBA) Accumulated Expenses (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Accumulated Expenses data on file, last reported at $125.1 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 75.31% year-over-year to $125.1 million in Q1 2026; TTM through Mar 2026 was $125.1 million, a 75.31% increase from a year earlier, with the FY2025 full-year figure at $121.7 million, up 91.8% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $125.1 million, up from $121.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for AKBA reached as high as $125.1 million in Q1 2026 and fell as low as $51.1 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $79.7 million across 5 years, with a median of $71.3 million in 2025.
• Across the five-year window, Accumulated Expenses tumbled 55.29% in 2023 and soared 103.81% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $75.8 million in 2022, then slipped by 10.61% to $67.7 million in 2023, then declined by 6.31% to $63.5 million in 2024, then soared by 91.8% to $121.7 million in 2025, then increased by 2.75% to $125.1 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $125.1 million in Q1 2026, $121.7 million in Q4 2025, and $106.4 million in Q3 2025.